Copyright Reports & Markets. All rights reserved.

Global Granulomatosis with Polyangiitis Drug Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Granulomatosis with Polyangiitis Drug

      • 1.1 Definition of Granulomatosis with Polyangiitis Drug
      • 1.2 Granulomatosis with Polyangiitis Drug Segment by Type
        • 1.2.1 Global Granulomatosis with Polyangiitis Drug Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Benralizumab
        • 1.2.3 Avacopan
        • 1.2.4 Rituximab Biosimilar
        • 1.2.5 Others
      • 1.3 Granulomatosis with Polyangiitis Drug Segment by Applications
        • 1.3.1 Global Granulomatosis with Polyangiitis Drug Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
        • 1.3.4 Others
      • 1.4 Global Granulomatosis with Polyangiitis Drug Overall Market
        • 1.4.1 Global Granulomatosis with Polyangiitis Drug Revenue (2014-2025)
        • 1.4.2 Global Granulomatosis with Polyangiitis Drug Production (2014-2025)
        • 1.4.3 North America Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)
        • 1.4.4 Europe Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)
        • 1.4.5 China Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)
        • 1.4.6 Japan Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)
        • 1.4.8 India Granulomatosis with Polyangiitis Drug Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug
      • 2.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
      • 2.4 Industry Chain Structure of Granulomatosis with Polyangiitis Drug

      3 Development and Manufacturing Plants Analysis of Granulomatosis with Polyangiitis Drug

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Granulomatosis with Polyangiitis Drug Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Granulomatosis with Polyangiitis Drug
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Granulomatosis with Polyangiitis Drug Production and Capacity Analysis
      • 4.2 Granulomatosis with Polyangiitis Drug Revenue Analysis
      • 4.3 Granulomatosis with Polyangiitis Drug Price Analysis
      • 4.4 Market Concentration Degree

      5 Granulomatosis with Polyangiitis Drug Regional Market Analysis

      • 5.1 Granulomatosis with Polyangiitis Drug Production by Regions
        • 5.1.1 Global Granulomatosis with Polyangiitis Drug Production by Regions
        • 5.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Regions
      • 5.2 Granulomatosis with Polyangiitis Drug Consumption by Regions
      • 5.3 North America Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.3.1 North America Granulomatosis with Polyangiitis Drug Production
        • 5.3.2 North America Granulomatosis with Polyangiitis Drug Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Granulomatosis with Polyangiitis Drug Import and Export
      • 5.4 Europe Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.4.1 Europe Granulomatosis with Polyangiitis Drug Production
        • 5.4.2 Europe Granulomatosis with Polyangiitis Drug Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Granulomatosis with Polyangiitis Drug Import and Export
      • 5.5 China Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.5.1 China Granulomatosis with Polyangiitis Drug Production
        • 5.5.2 China Granulomatosis with Polyangiitis Drug Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Granulomatosis with Polyangiitis Drug Import and Export
      • 5.6 Japan Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.6.1 Japan Granulomatosis with Polyangiitis Drug Production
        • 5.6.2 Japan Granulomatosis with Polyangiitis Drug Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Granulomatosis with Polyangiitis Drug Import and Export
      • 5.7 Southeast Asia Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.7.1 Southeast Asia Granulomatosis with Polyangiitis Drug Production
        • 5.7.2 Southeast Asia Granulomatosis with Polyangiitis Drug Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Granulomatosis with Polyangiitis Drug Import and Export
      • 5.8 India Granulomatosis with Polyangiitis Drug Market Analysis
        • 5.8.1 India Granulomatosis with Polyangiitis Drug Production
        • 5.8.2 India Granulomatosis with Polyangiitis Drug Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Granulomatosis with Polyangiitis Drug Import and Export

      6 Granulomatosis with Polyangiitis Drug Segment Market Analysis (by Type)

      • 6.1 Global Granulomatosis with Polyangiitis Drug Production by Type
      • 6.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type
      • 6.3 Granulomatosis with Polyangiitis Drug Price by Type

      7 Granulomatosis with Polyangiitis Drug Segment Market Analysis (by Application)

      • 7.1 Global Granulomatosis with Polyangiitis Drug Consumption by Application
      • 7.2 Global Granulomatosis with Polyangiitis Drug Consumption Market Share by Application (2014-2019)

      8 Granulomatosis with Polyangiitis Drug Major Manufacturers Analysis

      • 8.1 Bionovis SA
        • 8.1.1 Bionovis SA Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.1.2 Bionovis SA Product Introduction, Application and Specification
        • 8.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Bristol-Myers Squibb Company
        • 8.2.1 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.2.2 Bristol-Myers Squibb Company Product Introduction, Application and Specification
        • 8.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 ChemoCentryx Inc
        • 8.3.1 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.3.2 ChemoCentryx Inc Product Introduction, Application and Specification
        • 8.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Coherus BioSciences Inc
        • 8.4.1 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.4.2 Coherus BioSciences Inc Product Introduction, Application and Specification
        • 8.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Genor BioPharma Co Ltd
        • 8.5.1 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.5.2 Genor BioPharma Co Ltd Product Introduction, Application and Specification
        • 8.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 GlaxoSmithKline Plc
        • 8.6.1 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.6.2 GlaxoSmithKline Plc Product Introduction, Application and Specification
        • 8.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Iltoo Pharma
        • 8.7.1 Iltoo Pharma Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.7.2 Iltoo Pharma Product Introduction, Application and Specification
        • 8.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Panacea Biotec Ltd
        • 8.8.1 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.8.2 Panacea Biotec Ltd Product Introduction, Application and Specification
        • 8.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Sandoz International GmbH
        • 8.9.1 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.9.2 Sandoz International GmbH Product Introduction, Application and Specification
        • 8.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 The International Biotechnology Center (IBC) Generium
        • 8.10.1 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Production Sites and Area Served
        • 8.10.2 The International Biotechnology Center (IBC) Generium Product Introduction, Application and Specification
        • 8.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served

      9 Development Trend of Analysis of Granulomatosis with Polyangiitis Drug Market

      • 9.1 Global Granulomatosis with Polyangiitis Drug Market Trend Analysis
        • 9.1.1 Global Granulomatosis with Polyangiitis Drug Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Granulomatosis with Polyangiitis Drug Regional Market Trend
        • 9.2.1 North America Granulomatosis with Polyangiitis Drug Forecast 2019-2025
        • 9.2.2 Europe Granulomatosis with Polyangiitis Drug Forecast 2019-2025
        • 9.2.3 China Granulomatosis with Polyangiitis Drug Forecast 2019-2025
        • 9.2.4 Japan Granulomatosis with Polyangiitis Drug Forecast 2019-2025
        • 9.2.5 Southeast Asia Granulomatosis with Polyangiitis Drug Forecast 2019-2025
        • 9.2.6 India Granulomatosis with Polyangiitis Drug Forecast 2019-2025
      • 9.3 Granulomatosis with Polyangiitis Drug Market Trend (Product Type)
      • 9.4 Granulomatosis with Polyangiitis Drug Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Granulomatosis with Polyangiitis Drug Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Granulomatosis with Polyangiitis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Granulomatosis with Polyangiitis Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Granulomatosis with Polyangiitis Drug market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Granulomatosis with Polyangiitis Drug in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Granulomatosis with Polyangiitis Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Bionovis SA
        Bristol-Myers Squibb Company
        ChemoCentryx Inc
        Coherus BioSciences Inc
        Genor BioPharma Co Ltd
        GlaxoSmithKline Plc
        Iltoo Pharma
        Panacea Biotec Ltd
        Sandoz International GmbH
        The International Biotechnology Center (IBC) Generium

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Benralizumab
        Avacopan
        Rituximab Biosimilar
        Others

        Segment by Application
        Hospital
        Clinic
        Others

        Buy now